Recent News

• 09.15.2025 - aTyr Pharma Conference Call
• 09.15.2025 - aTyr Pharma Conference Call
• 09.15.2025 - aTyr Pharma Announces Topline Results from Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis
• 09.15.2025 - aTyr Pharma Announces Topline Results from Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis
• 09.15.2025 - aTyr Pharma Announces Topline Results from Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis
• 09.05.2025 - aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 09.05.2025 - aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 09.05.2025 - aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 08.07.2025 - aTyr Pharma Announces Second Quarter 2025 Results and Provides Corporate Update
• 08.07.2025 - aTyr Pharma Announces Second Quarter 2025 Results and Provides Corporate Update

Recent Filings

• 09.15.2025 - 8-K Current report
• 09.15.2025 - EX-99.1 EX-99.1
• 08.18.2025 - EFFECT Notice of Effectiveness
• 08.08.2025 - 8-K/A Current report
• 08.07.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.07.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 08.07.2025 - EX-99.1 EX-99.1
• 08.07.2025 - S-3 Registration statement under Securities Act of 1933
• 08.07.2025 - 8-K Current report